Sugi Predict

Sugi Predict / Compounds / SCHEMBL1065225

SCHEMBL1065225

SCHEMBL1065225

CCOC(=O)C(=O)CC(=O)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ PKM P14618 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ MITF O75030 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ CTNNB1 P35222 1/20 0.49
▸ WNT3A P56704 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.48
▸ POLB P06746 1/20 0.48
▸ MAPT P10636 5/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ TSHR P16473 1/20 0.46
▸ ALDH3A1 P30838 1/20 0.46
▸ GRM4 Q14833 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4302986 0.93 SMN1; SMN2 (0.46) SMN1; SMN2KDM4EPKMNPC1MITF
SCHEMBL2914066 0.86 ALDH1A1 (0.50) SMN1; SMN2KDM4EPKMNPC1MITF
SCHEMBL25832842 0.86 CTNNB1 (0.43) SMN1; SMN2KDM4EPKMNPC1MITF
SCHEMBL601821 0.84 LMNA (0.54) SMN1; SMN2KDM4EPKMNPC1MITF
SCHEMBL5479636 0.81 CES2 (0.60) SMN1; SMN2KDM4EPKMNPC1MITF
SCHEMBL2916521 0.81 ALDH1A1 (0.45) SMN1; SMN2KDM4EPKMNPC1RAB9A
SCHEMBL13855351 0.79 ALDH1A1 (0.58) SMN1; SMN2KDM4EPKMRAB9ACTNNB1
SCHEMBL2917709 0.79 KDM4E (0.43) SMN1; SMN2KDM4ERAB9AALDH1A1POLB
SCHEMBL2917891 0.79 NPC1 (0.50) SMN1; SMN2KDM4ENPC1RAB9APOLB
SCHEMBL2915799 0.79 P2RX7 (0.51) SMN1; SMN2KDM4EPKMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325702-B2 ATF6 inhibitors and uses thereof ALTOS LABS, INC. (US) 2025-06-10 — — US disclosed
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2024-04-18 — — US disclosed
US-20240109897-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-04-04 — — US disclosed
CN-117157296-A Modulators of FPR1 and methods of use thereof 首都医科大学附属北京天坛医院 2023-12-01 — — CN disclosed
CN-116425754-A Aromatic heterobicyclic compounds and antiviral uses thereof 苏州爱科百发生物医药技术有限公司 2023-07-14 — — CN disclosed
WO-2023125845-A1 HETEROAROMATIC BICYCLIC COMPOUND AND ANTIVIRAL APPLICATION THEREOF 苏州爱科百发生物医药技术有限公司 2023-07-06 — — WO disclosed
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 — — EP disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
EP-3774782-A2 ATF6 INHIBITORS AND USES THEREOF Black Belt TX Ltd (GB) 2021-02-17 — — EP disclosed
EP-1785418-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 — — EP disclosed
CN-1902191-A Amidopyrazole derivative DAIICHI SEIYAKU CO (JP) 2007-01-24 — — CN disclosed
EP-1698626-A1 AMIDOPYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 — — EP disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 — — US disclosed
CN-1759110-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2006-04-12 — — CN disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 — — EP disclosed
US-5942622-A NOVEL COMPOUNDS FOR TREATING ILLNESS RESULTING FROM ABNORMAL STIMULATION OF ENDOTHELIAL RECEPTORS; FOR EXAMPLE: 4-((6-CHLORO-1,3-BENZODIOXOL-5-YL)METHYL)-1-(CYCLOHEXYLMETHYL) -3-(2-PYRIDINYL)-1H-PYRAZOLE-5-CARBOXYLATE HOECHST MARION ROUSSEL (FR) 1999-08-24 — — US disclosed
US-4735957-A ANTIULCER AGENTS, CARDIOTONIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-04-05 — — US disclosed
US-4649146-A ANTIULCER FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-03-10 — — US disclosed
EP-0117082-A2 Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-08-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 SMN1; SMN2 1522/4885KDM4E 4305/4885PKM 3639/4885
US-12325702-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 SMN1; SMN2 1522/4885KDM4E 4305/4885PKM 3639/4885
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 SMN1; SMN2 3778/4885KDM4E 4322/4885PKM 1036/4885
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 SMN1; SMN2 1522/4885KDM4E 4305/4885PKM 3639/4885
US-20240109897-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME FPR1, FPR2, FPR3 SMN1; SMN2 2805/4885KDM4E 4841/4885PKM 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.